High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the phase 2b core study

被引：0
|
作者：
Bernstein, Jonathan A. [1 ,2 ]
Maurer, Marcus [3 ]
Gimenez-Arnau, Ana [4 ]
Soong, Weily [5 ]
Sitz, Karl [6 ]
Hua, Eva [7 ]
Barbier, Nathalie [8 ]
Barve, Avantika [9 ]
Severin, Thomas [8 ]
Janocha, Reinhold [8 ]
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Bernstein Clin Res Ctr, Cincinnati, OH USA
[3] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[4] Univ Autonoma Barcelona, Dept Dermatol, Hosp Mar Parc Salut Mar, Barcelona, Spain
[5] Clin Res Ctr Alabama, Alabama Allergy & Asthma Ctr, Birmingham, AL USA
[6] Little Rock Allergy & Asthma Clin, Clin Res Ctr, Little Rock, AR USA
[7] Shanghai Novartis Trading Ltd, Shanghai, Peoples R China
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27362
引用
收藏
页码：AB137 / AB137
页数：1
相关论文
共 50 条
  • [1] Ligelizumab Achieves High Rate of Complete Response in Patients with Moderate to Severe Chronic Spontaneous Urticaria
    Bernstein, J.
    Maurer, M.
    Gimenez-Arnau, A.
    Soong, W.
    Sussman, G.
    Metz, M.
    Lanier, B.
    Sitz, K.
    Hide, M.
    Manetsch, M.
    Hua, E.
    Barve, A.
    Severin, T.
    Janocha, R.
    SWISS MEDICAL WEEKLY, 2021, 151 : 12S - 12S
  • [2] Ligelizumab achieves high rate of complete response in patients with moderate to severe chronic spontaneous urticaria
    Bernstein, J. A.
    Maurer, M.
    Gimenez-Arnau, A.
    Soong, W.
    Sussman, G.
    Metz, M.
    Lanier, B.
    Sitz, K.
    Hide, M.
    Hua, E.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2020, 75 : 84 - 85
  • [3] High rate of complete response with ligelizumab in adults with moderate-to-severe chronic spontaneous urticaria
    Bernstein, J. A.
    Maurer, M.
    Gimenez-Arnau, A.
    Soong, W.
    Sussman, G.
    Metz, M.
    Lanier, B.
    Sitz, K.
    Hide, M.
    Hua, E.
    Barve, A.
    Severin, T.
    Janocha, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 : 57 - 57
  • [4] LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Soong, W.
    Lanier, B.
    Kobayashi, K.
    Barve, A.
    Hua, E.
    Janocha, R.
    Severin, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S28
  • [5] REMIBRUTINIB SHOWED GOOD STABILITY OF RESPONSE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY
    Tillinghast, J.
    Jain, V.
    Maurer, M.
    Gimenez-Arnau, A.
    Reich, A.
    Ortmann, C.
    Walsh, P.
    Haemmerle, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S41 - S41
  • [6] Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis
    Staubach, Petra
    Alvaro-Lozano, Montserrat
    Sekerel, Bulent Enis
    Maurer, Marcus
    Ben-Shoshan, Moshe
    Porter, Miriam
    Hua, Eva
    Ji, Yan
    Burciu, Alis
    Savelieva, Marina
    Severin, Thomas
    Drollmann, Anton
    Bienczak, Andrzej
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2023, 34 (07)
  • [7] Complete freedom from chronic spontaneous urticaria signs and symptoms is associated with sleep and dermatology quality-of-life improvements: Data from the phase 2b ligelizumab study
    Bernstein, Jonathan A.
    Gimenez-Arnau, Ana
    Hide, Michihiro
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB35 - AB35
  • [8] Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab
    Maurer, M.
    Gimenez-Arnau, A. M.
    Soong, W.
    Bernstein, J. A.
    Sussman, G.
    Metz, M.
    Lanier, B.
    Hide, M.
    Sitz, K.
    Hua, E.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2020, 75 : 86 - 86
  • [9] Retreatment with ligelizumab achieves over forty percent higher complete response rate in patients with chronic spontaneous urticaria originally treated with omalizumab
    Maurer, Marcus
    Gimenez-Arnau, Ana
    Soong, Weily
    Bernstein, Jonathan A.
    Sussman, Gordon
    Metz, Martin
    Lanier, Bobby
    Hide, Michihiro
    Sitz, Karl
    Hua, Eva
    Barve, Avantika
    Severin, Thomas
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (12): : 1669 - 1670
  • [10] Study design and rationale of a phase 3b extension study of ligelizumab in adult and adolescent patients with chronic spontaneous urticaria
    Severin, T.
    Maurer, M.
    Gimenez-Arnau, A. M.
    Hide, M.
    Sussman, G.
    Saini, S. S.
    Hua, E.
    Barve, A.
    Joubert, Y.
    Indermuehle, I.
    Janocha, R.
    ALLERGY, 2020, 75 : 446 - 447
12345